Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras

被引:23
|
作者
De Paepe, Boel [1 ]
机构
[1] Ghent Univ Hosp, Neuromuscular Reference Ctr, Corneel Heymanslaan 10, B-9000 Ghent, Belgium
来源
BIOMOLECULES | 2019年 / 9卷 / 01期
关键词
mitochondrial dysfunction; myositis; sporadic inclusion body myositis; SKELETAL-MUSCLE; DNA; ABNORMALITIES; PATHOLOGY; AUTOANTIBODIES; INFLAMMATION; MAINTENANCE; DYSFUNCTION; MITOPHAGY; CYTOKINES;
D O I
10.3390/biom9010015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The sporadic form of inclusion body myositis (IBM) is the most common late-onset myopathy. Its complex pathogenesis includes degenerative, inflammatory and mitochondrial aspects. However, which of those mechanisms are cause and which effect, as well as their interrelations, remain partly obscured to this day. In this review the nature of the mitochondrial dysregulation in IBM muscle is explored and comparison is made with other muscle disorders. Mitochondrial alterations in IBM are evidenced by histological and serum biomarkers. Muscular mitochondrial dynamics is disturbed, with deregulated organelle fusion leading to subsequent morphological alterations and muscle displays abnormal mitophagy. The tissue increases mitochondrial content in an attempt to compensate dysfunction, yet mitochondrial DNA (mtDNA) alterations and mild mtDNA depletion are also present. Oxidative phosphorylation defects have repeatedly been shown, most notably a reduction in complex IV activities and levels of mitokines and regulatory RNAs are perturbed. Based on the cumulating evidence of mitochondrial abnormality as a disease contributor, it is therefore warranted to regard IBM as a mitochondrial disease, offering a feasible therapeutic target to be developed for this yet untreatable condition.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Mitochondrial and inflammatory changes in sporadic inclusion body myositis
    Rygiel, K. A.
    Miller, J.
    Grady, J. P.
    Rocha, M. C.
    Taylor, R. W.
    Turnbull, D. M.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2015, 41 (03) : 288 - 303
  • [2] Mitochondrial DNA depletion in sporadic inclusion body myositis
    Bhatt, Padmanabh S.
    Tzoulis, Charalampos
    Balafkan, Novin
    Miletic, Hrvoje
    Gia Tuong Thi Tran
    Sanaker, Petter Schandl
    Bindoff, Laurence A.
    NEUROMUSCULAR DISORDERS, 2019, 29 (03) : 242 - 246
  • [3] Mitochondrial DNA rearrangements in sporadic inclusion body myositis
    Rygiel, K. A.
    Tuppen, H.
    Reeve, A.
    Miller, J.
    Taylor, R.
    Turnbull, D. M.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S37 - S37
  • [4] McArdle disease and sporadic inclusion body myositis
    Scarpelli, M.
    Vattemi, G.
    Filosto, M.
    Krause, S.
    Marini, M.
    Tomelleri, G.
    Tonin, P.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2009, 35 (04) : 442 - 445
  • [5] Functional relevance of mitochondrial abnormalities in sporadic inclusion body myositis
    Joshi, Pushpa Raj
    Vetterke, Mirjam
    Hauburger, Anja
    Tacik, Pawel
    Stoltenburg, Gisela
    Hanisch, Frank
    JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (11) : 1959 - 1963
  • [6] Mitochondrial defects in sporadic inclusion body myositis-causes and consequences
    Iu, Elsie Chit Yu
    So, Ho
    Chan, Chi Bun
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [7] Mitochondrial DNA abnormalities and the pathogenesis of sporadic inclusion-body myositis
    Horvath, R
    Fu, K
    Genge, A
    Karpati, G
    Shoubridge, EA
    NEUROLOGY, 1996, 46 (02) : 1007 - 1007
  • [8] Update on sporadic inclusion body myositis
    Hohlfeld, Reinhard
    BRAIN, 2011, 134 : 3141 - 3145
  • [9] Sporadic inclusion body myositis - a myodegenerative disease or an inflammatory myopathy
    Weihl, C. C.
    Mammen, A. L.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2017, 43 (01) : 82 - 91
  • [10] β-catenin in sporadic inclusion body myositis
    Shim, C. Y.
    Bettolo, C. Marini
    Singh, P.
    Rakowicz, W.
    Lane, R. J.
    Roncaroli, F.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2013, 39 : 35 - 36